Health Economics›Gastrointestinal stromal tumor›Metastatic or unresectable disease

Metastatic or unresectable disease

Gastrointestinal stromal tumor · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Best supportive care Partial	—	—	—	2.3 mo	—	—	—	1
Placebo Partial	—	—	—	0.9 mo	7.6 mo	—	—	4

2 of 2 regimens shown